๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Acute Myeloid Leukemia
Clinical trial register · China

Acute Myeloid Leukemia Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Suzhou 20 Hangzhou 18 Beijing 14 Tianjin 14 Shanghai 10
Narrow the registerReset
Recruitment status
Phase
Site location
Suzhou20 Hangzhou18 Beijing14 Tianjin14 Shanghai10
All 41 locations
Target enrolment
to

Acute Myeloid Leukemia trials in China

98 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Universal CAR-T Cells Targeting AML
NCT05995041Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2027-06-30
Not yet open
Universal 4SCAR7U Targeting CD7-positive Malignancies
NCT05995028T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2027-06-30
Not yet open
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
NCT04033302T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
NCT03222674Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2026-12-31
Active, closed
Chidamide in HR-AML
NCT07822789Acute Myeloid Leukemia, Maintenance Therapy
Guangdong Second Provincial General Hospital
Observational
33
Guangzhou
2026-07-27
Not yet open
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
NCT07751588Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
25
Tianjin
2026-07-11
Not yet open
Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
NCT07664839Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation
Shen yang
Phase 2
148
Shanghai
2026-07-01
Not yet open
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
228
Tianjin
2026-06-01
Recruiting
VA Consolidation in Intermediate-Risk AML
NCT07672262Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
The First Affiliated Hospital of Soochow University
Phase 2
226
Suzhou
2026-06-01
Not yet open
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
NCT07575412Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
180
Suzhou
2026-06
Not yet open
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
NCT07562568Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
160
Suzhou
2026-06
Recruiting
Study of SA+X in the Treatment of Newly Diagnosed AML
NCT07548710Acute Myeloid Leukemia
Ruijin Hospital
Phase 2
205
Shanghai
2026-05-01
Recruiting
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
NCT07563179Acute Myeloid Leukemia, Relapse/Recurrence
Shenzhen University General Hospital
Phase 2
10
Shenzhen
2026-04-21
Recruiting
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
NCT07255872Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
216
Tianjin
2026-04-02
Not yet open
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
NCT07483749Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
The Children's Hospital of Zhejiang University School of Medicine
Observational
400
Hangzhou, Ningbo
2026-03-25
Not yet open
IFN-ฮฑ in Relapse Prevention.
NCT07449286Acute Myeloid Leukemia, Myelodysplastic Syndromes
Peking University People's Hospital
Phase 2
100
Beijing
2026-03-01
By invitation
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
NCT07651176Acute Myeloid Leukemia, Lisaftoclax
First Affiliated Hospital of Zhejiang University
Phase 2/3
267
Hangzhou
2026-03-01
Recruiting
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
NCT07425782Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk
The First Affiliated Hospital of Soochow University
Phase 2
216
Suzhou
2026-02-01
Recruiting
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
NCT07259707Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive, Intermediate Risk Acute Myeloid Leukemia, Fit Patients
First Affiliated Hospital of Zhejiang University
Phase 2
25
Hangzhou
2026-01-25
Recruiting
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
NCT07144020Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1
50
Hangzhou
2025-09-05
Recruiting
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
NCT07743112Acute Myeloid Leukemia
Maxinovel Pty., Ltd.
Phase 2
43
Tianjin
2025-09-05
Recruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT07183878Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University
Not applicable
138
Hangzhou
2025-08-20
Recruiting
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
NCT07108530Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 2
50
Taiyuan
2025-08-06
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
NCT07763054Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Observational
30
Hainan
2025-08-01
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Recruiting
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
NCT07106749Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
NCT07028086Acute Myeloid Leukemia, Myeloid Sarcoma
Ruijin Hospital
Phase 2
48
Shanghai
2025-06-20
Recruiting
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
NCT07078591Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2
50
Beijing
2025-06-20
Recruiting
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
NCT07321626Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment, HSCT
First Affiliated Hospital of Zhejiang University
Phase 1
130
Hangzhou
2025-06-01
Recruiting
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
NCT07007949Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib
The First Affiliated Hospital of Soochow University
Phase 2
42
Suzhou
2025-06-01
Recruiting
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
NCT06980155Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
60
Shanghai
2025-05-30
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06880354Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
37
Tianjin
2025-05-22
Not yet open
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
NCT06900088Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-04-25
Recruiting
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
NCT06737523Acute Myeloid Leukemia, Relapse, Refractory AML
The First Affiliated Hospital of Xiamen University
Phase 1
30
Xiamen
2025-03-15
Recruiting
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
NCT06245746Acute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
9
Wuhan
2025-02-26
By invitation
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
NCT06697327Leukemia, Myeloid, Acute, Acute Myeloid Leukemia
Anhui Medical University
Not applicable
94
Hefei
2025-02-01
Recruiting
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
NCT06816134Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
The First Affiliated Hospital of Soochow University
Phase 2
48
Suzhou
2025-01-30
Recruiting
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
NovaOnco Therapeutics Co., Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
NCT06762132Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1
27
Hangzhou
2025-01-10
Recruiting
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
NCT06746519Acute Myeloid Leukemia
Chen Suning
Phase 1/2
135
Suzhou
2024-12-25
Recruiting
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
NCT06651866Acute Myeloid Leukemia
The First Affiliated Hospital of Xiamen University
Phase 1
18
Xiamen
2024-12-12
Recruiting
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
NCT06452732Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Peking University People's Hospital
Observational
283
Beijing
2024-11-01
Active, closed
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT06497062Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 2
47
Shanghai
2024-10-30
Recruiting
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
NCT06458257Acute Myeloid Leukemia
Ruijin Hospital
Observational
50
Shanghai
2024-10-19
Not yet open
Twice-per-weekSelinexor, 2 Days Melphalan
NCT06613035Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Recruiting
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244Acute Myeloid Leukemia
Ruijin Hospital
Observational
90
Shanghai
2024-09-21
Not yet open
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
NCT06470841Acute Myeloid Leukemia
Navy General Hospital, Beijing
Phase 2
85
Beijing
2024-09-20
Recruiting
Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy
NCT07551037Acute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy
Fujian Medical University Union Hospital
Phase 1
90
Fuzhou
2024-09-01
Recruiting
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT06451861Acute Myeloid Leukemia
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Recruiting
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
NCT06386302AML, Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
184
Tianjin
2024-08-05
Recruiting
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06571825Acute Myeloid Leukemia
He Huang
Phase 4
118
Hangzhou
2024-07-17
Recruiting
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
NCT06420063AML, Acute Myeloid Leukemia, AML, Adult Recurrent, AML, Adult
Essen Biotech
Phase 1/2
85
Beijing
2024-07-10
Recruiting
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
NCT06621199Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University
Phase 2
42
Hangzhou
2024-07-08
Recruiting
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
NCT06483906Acute Myeloid Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
56
Shanghai
2024-07-02
Recruiting
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3
486
Tianjin, Hangzhou
2024-06-11
Recruiting
MRD Response-adapted Allo-HSCT for Adverse-risk AML
NCT06301425Acute Myeloid Leukemia
Peking University People's Hospital
Not applicable
178
Beijing
2024-05-24
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069Acute Myeloid Leukemia
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Recruiting
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
NCT07584889B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase 1/2
10
Shenzhen
2024-04-20
Recruiting
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
NCT06928376Acute Myeloid Leukemia, First Line Therapy
Chinese PLA General Hospital
Phase 2
160
Beijing
2024-04-18
Recruiting
VA vs DA for Newly Diagnosed Hig-risk AML
NCT05939180Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2/3
116
Suzhou
2024-04-01
Recruiting
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
NCT06234904Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1
18
Suzhou
2024-03-26
Recruiting
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
NCT06206174Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
Shenzhen TargetRx Co., Ltd.
Phase 1/2
30
Tianjin
2024-03-06
Recruiting
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
NCT06220162Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
32
Suzhou
2024-02-01
Recruiting
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
NCT06111612Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
50
Shanghai
2024-01-20
Active, closed
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
NCT07437170Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia
The Children's Hospital of Zhejiang University School of Medicine
Phase 2
10
Hangzhou
2024-01-01
Recruiting
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NCT06232694Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
54
Nanjing
2024-01-01
Active, closed
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFฮฒ::MYH11(+) AML
NCT06429098Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2024-01-01
Recruiting
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
NCT06221683AML, Childhood, Acute Myeloid Leukemia
Children's Hospital of Soochow University
Phase 2
500
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-01-01
Recruiting
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT05991908Acute Myeloid Leukemia, Myelodysplastic Syndromes
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Recruiting
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
NCT06046313Acute Myeloid Leukemia, Myelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University
Phase 2
120
Hangzhou
2023-10-19
Active, closed
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
NCT06066242Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
113
Tianjin
2023-10-01
Active, closed
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy
NCT06024031Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2
30
Beijing
2023-09-10
Recruiting
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
NCT05659732Acute Myeloid Leukemia, Lymphoma, Mantle-Cell
DrugPEP07
PharmaEngine
Phase 1
32
2023-07-17
Recruiting
The Maintenance Treatment of "ITIVA" in AML Patients
NCT06256627Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-ฮฑ-1b
Henan Cancer Hospital
Not applicable
130
Zhengzhou
2023-07-11
Recruiting
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
NCT05909293Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2023-04-12
Recruiting
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
NCT05772273Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2023-03-15
Recruiting
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
NCT05805098Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2/3
60
Suzhou
2023-03-01
Recruiting
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
198
Nanchang, Suzhou, Zhengzhou
2023-02-14
Recruiting
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
NCT06802718Acute Myeloid Leukemia
Peking University People's Hospital
Phase 3
96
Beijing
2023-01-01
Recruiting
CAV Regimen for R/R AML
NCT05657639Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
68
Suzhou
2022-10-01
Recruiting
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
NCT06827899Acute Myeloid Leukemia
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-07-01
Recruiting
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
NCT05445011Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
12
Wuhan
2022-06-14
Recruiting
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
NCT06328179Acute Myeloid Leukemia
Huai'an First People's Hospital
Not applicable
34
Huai'an
2022-05-24
Active, closed
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
NCT05356169Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
312
Tianjin
2022-05-19
Recruiting
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ยฑ Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT07561892Acute Myeloid Leukemia, Newly Diagnosed, Chemotherapy Effect
Fujian Medical University Union Hospital
Phase 4
100
Fuzhou
2022-04-01
Recruiting
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
NCT04662294Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1
108
Hangzhou
2021-11-18
Recruiting
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
NCT06536010Acute Myeloid Leukemia
Yang Xiaotian
Not applicable
50
Huai'an
2021-11-03
Active, closed
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05029141Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML
The First Affiliated Hospital of Soochow University
Phase 2
21
Suzhou
2021-09-01
Active, closed
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
NCT04980885Acute Myeloid Leukemia
Akeso
Phase 1/2
68
Hangzhou
2021-08-13
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Not yet open
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
NCT04658004Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1
36
Hangzhou
2021-01-15
Recruiting
National Longitudinal Cohort of Hematological Diseases
NCT04645199Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,300
Tianjin
2020-12-01
Not yet open
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
NCT04599543Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1
36
Hangzhou
2020-11-15
Active, closed
Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia
NCT04415008CEBPA Double Mutation, Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
61
Tianjin
2020-06-01
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
AbbVie
Phase 3
165
2019-09-06
Active, closed
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
NCT06379360Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
60
Suzhou
2019-07-01
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
Novartis Pharmaceuticals
Phase 4
279
Hangzhou, Beijing
2015-03-05
Rows per page Showing 1–98 of 98
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/acute-myeloid-leukemia

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 98 of those studies listing the condition Acute Myeloid Leukemia.

How many Acute Myeloid Leukemia trials are recruiting in China?

67 of the 98 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 16 have not yet opened recruitment, 13 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Acute Myeloid Leukemia), 98 studies
PhaseStudiesRecruitingShare
Phase 2342134.7%
Phase 1151215.3%
Not applicable11911.2%
Observational969.2%
Phase 1/2858.2%
Phase 2/3646.1%
Phase 3646.1%
Phase EARLY_PHASE1646.1%
Phase 4323.1%

Most active sponsors

Lead sponsors with the most studies (Acute Myeloid Leukemia)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Soochow University149
Institute of Hematology & Blood Diseases Hospital, China104
First Affiliated Hospital of Zhejiang University65
Peking University People's Hospital53
Zhejiang University53
Ruijin Hospital44
Shenzhen Geno-Immune Medical Institute40
Shanghai Jiao Tong University School of Medicine32
The First Affiliated Hospital of Xiamen University33
AbbVie21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.